Suppr超能文献

奥密克戎作为一种新型 SARS-COVID-19 变体的最新研究进展:进化、基因突变和未来展望。

Recent highlights on Omicron as a new SARS-COVID-19 variant: evolution, genetic mutation, and future perspectives.

机构信息

Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research-Raebareli, Lucknow, India.

Department of Pharmaceutical Chemistry, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia.

出版信息

J Drug Target. 2022 Jul;30(6):603-613. doi: 10.1080/1061186X.2022.2056187. Epub 2022 Mar 28.

Abstract

COVID-19 has affected the lives of billions of people and is a causative agent for millions of deaths. After 23 months of the first reported case of COVID-19, on 25th November 2020, a new SARS-COVID-19 variant, i.e. Omicron was reported with a WHO tagline of VoC that trembled the world with its infectivity rate. This fifth VoC raised the concern about neutralising ability and adequate control of SARS-COVID-19 infection due to mass vaccination drive (nearly more than 4.7 billion individuals got vaccinated globally till December 2021). However, the present scenario of VoCs highlights the importance of vaccination and public health measures that need to be followed strictly to prevent the fatality from Omicron. The world still needs to overcome the hesitancy that poses a major barrier to the implementation of vaccination. This review highlights the SARS-COVID-19 situation and discusses in detail the mutational events that occurred at a cellular level in different variants over time. This article is dedicated to the scientific findings reported during the recent outbreak of 2019-2022 and describes their symptoms, disease, spread, treatment, and preventive action advised. The article also focuses on the treatment options available for Covid-19 and the update of Omicron by expert agencies.

摘要

COVID-19 已经影响了数十亿人的生活,是数百万人死亡的原因。在首例 COVID-19 报告 23 个月后,即 2020 年 11 月 25 日,一种新的 SARS-COVID-19 变体,即奥密克戎被报告,世界卫生组织的一个标签是“VOC”,其传染性让世界震惊。这种第五个 VOC 引起了人们对中和能力和 SARS-COVID-19 感染的充分控制的关注,因为大规模的疫苗接种运动(截至 2021 年 12 月,全球已有近 47 亿人接种疫苗)。然而,目前 VOC 的情况突出了接种疫苗和公共卫生措施的重要性,需要严格遵守这些措施,以防止奥密克戎的致命性。世界仍需克服实施疫苗接种所面临的犹豫,这是实施疫苗接种的主要障碍。这篇综述强调了 SARS-COVID-19 的情况,并详细讨论了不同变体在细胞水平上随时间发生的突变事件。本文致力于报道最近 2019-2022 年爆发期间的科学发现,并描述了它们的症状、疾病、传播、治疗和建议的预防措施。文章还重点介绍了针对新冠病毒的治疗选择和专家机构对奥密克戎的更新。

相似文献

本文引用的文献

1
Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic.奥密克戎新冠病毒变体:新冠疫情的新篇章。
Lancet. 2021 Dec 11;398(10317):2126-2128. doi: 10.1016/S0140-6736(21)02758-6. Epub 2021 Dec 3.
2
Drug repurposing strategies and key challenges for COVID-19 management.药物重定位策略和管理 COVID-19 的关键挑战。
J Drug Target. 2022 Apr;30(4):413-429. doi: 10.1080/1061186X.2021.2013852. Epub 2021 Dec 9.
7
SARS-CoV-2 variants, spike mutations and immune escape.SARS-CoV-2 变体、刺突突变和免疫逃逸。
Nat Rev Microbiol. 2021 Jul;19(7):409-424. doi: 10.1038/s41579-021-00573-0. Epub 2021 Jun 1.
8
Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant.NVX-CoV2373 新冠疫苗对 B.1.351 变异株的有效性。
N Engl J Med. 2021 May 20;384(20):1899-1909. doi: 10.1056/NEJMoa2103055. Epub 2021 May 5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验